โรคเกาต์และการรักษา Gout and Treatment
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Kramer HM, Curhan G. The association between gout and nephrolithiasis: the national health and nutrition examination survey III, 1988-1994. Am J Kidney Dis 2002; 40: 37-42.
Bomalaski JS, Holtsberg FW,Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase PEG20): biochemical rationale and preclinical studies. J Rheumatol 2002; 29: 1942-9.
Campion EW, Glynn RJ, DeLabry LO. Asymtomatic hyperuricemia: risks and consequences in the normative aging study. Am J Med 1987; 82: 421-6.
Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-6.
Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974 -9.
Terkeltuab RA. Pathogenesis and treatment of crystalinduced inflammation. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of Rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins 2001: p 2329-47.
Ritter J, Herr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696-9.
Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21: 1325-7.
Taylor CT, Brooks NC, Kelly KW. Corticotropin for acute management of gout. Ann Pharmacother 2001;35: 365-8.
Bonnel RA, villalba ML, Karwoski CB, Bietz J. Death associated with intravenous colchicines administration. bioe J Emerg Med 2002; 22: 385-7.
Yamanaka H, Togashi R, Hakoda M. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13-8.
Pererex-Ruiz F, Calabizo M, Erauskin GG, Ruib Herrerro-Beites AM. Renal under excretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47: 610-3.
Becker MA. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 1988; 14: 377-94.
Perex-Ruiz F,A Alonzo-Ruiz A, Calabozo M, Hererro-Beites A,Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann RheumDis 1998; 57: 545-9.
Perex-Ruiz F, Calabozo M, Pijoan JI, Hererro-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-60.
Fam AG, Dunne SM, lazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231-8.
Hande KR, Noone RM, Stone WJ. Severe allopuronol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.